share_log

Roth MKM Initiates Coverage On Chemomab Therapeutics With Buy Rating, Announces Price Target of $7

Roth MKM Initiates Coverage On Chemomab Therapeutics With Buy Rating, Announces Price Target of $7

Roth MKM以買入評級開始對Chemomab Therapeutics進行報道,宣佈目標股價爲7美元
Benzinga ·  2023/10/06 08:56

Roth MKM analyst Dylan Dupuis initiates coverage on Chemomab Therapeutics (NASDAQ:CMMB) with a Buy rating and announces Price Target of $7.

Roth MKM分析師Dylan Dupuis以買入評級啟動對Chemomab治療公司(納斯達克:CMMB)的報道,並宣佈目標價為7美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論